[1] COOPER D S,DOHERTY G M,HAUGEN B R,et al.Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer:the American thyroid association(ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2009,19(11):1167-1214.
[2] DURANTE C,HADDY N,BAUDIN E,et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy[J].Clin Endocrinol Metab,2006,91(8):2892-2899.
[3] FRANCIS G L,WAGUESPACK S G,BAUER A J,et al.Management guidelines for children with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2015,25(7):716-759.
[4] 谢艳,蒋玲,周克华,等.远处转移分化型甲状腺癌碘难治危险因素及生存分析[J].中华内分泌代谢杂志,2017,33(5):387-391.
[5] 瞿金妙.老年甲状腺癌患者的手术治疗及预后分析[J].中华老年医学杂志,2012,31(12):1079-1081.
[6] 刘美宏,毕洁领,唐文.miR-193a和IL17RD在甲状腺癌中的表达及其临床意义[J].现代医学, 2018,46(7):765-769.
[7] XU B,TUTTLE R M,SABRA M M,et al.Primary thyroid carcinoma with low-risk histology and distant metastases:clinicopathologic and molecular characteristics[J].Thyroid,2017,27(5):632-640.
[8] 林岩松,张彬,梁智勇,等.复发转移性分化型甲状腺癌诊治共识[J].中国癌症杂志,2015,25(7):481-496.
[9] ZHOU Q,CHEN J,FENG J,et al.Sostdc1 inhibits follicular thyroid cancer cell proliferation, migration,and emt via suppressing pi3k/akt and mapk/erk signaling pathways[J].Mol Cell Biochem,2017,435(1-2):87-95.
[10] ROTHENBERG S M,MCFADDEN D G,PALMER E L,et al.Redifferentiation of iodine-refractory braf v600e-mutant metastatic papillary thyroid cancer with dabrafenib[J].Clin Cancer Res,2015,21(5):1028-1035. |